<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564677</url>
  </required_header>
  <id_info>
    <org_study_id>DM-ZOL-02</org_study_id>
    <nct_id>NCT04564677</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Clinical Outcome of a Modified d'Hoore Technique for Laparoscopic Ventral Mesh Rectopexy</brief_title>
  <acronym>POP-01</acronym>
  <official_title>A Prospective Study Evaluating the Clinical Outcome of a Modified d'Hoore Technique for Laparoscopic Ventral Mesh Rectopexy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duomed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duomed</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to evaluate the clinical outcome of a modified&#xD;
      d'Hoore technique for laparoscopic ventral mesh rectopexy in patients with primary rectal&#xD;
      prolapse, rectocele and/or enterocele.The goal of the study will be achieved by reporting the&#xD;
      peri- and postoperative complications ((serious) adverse events), recurrences and&#xD;
      re-interventions. Pre-operative to postoperative changes in pain, functional outcome and&#xD;
      quality of life will be evaluated as well.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural efficacy - Number of participants with (serious) adverse events</measure>
    <time_frame>During procedure</time_frame>
    <description>Number of participants with (serious) adverse events ≥ grade II Clavien-Dindo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural efficacy - Conversion rate to laparotomy during the index procedure</measure>
    <time_frame>During procedure</time_frame>
    <description>Number of conversions to laparotomy during the index procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural efficacy - Number of participants with (serious) adverse events</measure>
    <time_frame>At discharge (assessed up to 1 week)</time_frame>
    <description>Number of participants with (serious) adverse events ≥ grade II Clavien-Dindo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural efficacy - Number of re-interventions</measure>
    <time_frame>At discharge (assessed up to 1 week)</time_frame>
    <description>Number of re-interventions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural efficacy - Number of participants with (serious) adverse events</measure>
    <time_frame>Follow-up 1: 6 - 10 weeks after the procedure</time_frame>
    <description>Number of participants with (serious) adverse events ≥ grade II Clavien-Dindo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural efficacy - Number of re-interventions</measure>
    <time_frame>Follow-up 1: 6 - 10 weeks after the procedure</time_frame>
    <description>Number of re-interventions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural efficacy - Number of post-operative recurrences</measure>
    <time_frame>Follow-up 1: 6 - 10 weeks after the procedure</time_frame>
    <description>Number of post-operative recurrences</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural efficacy - Number of participants with (serious) adverse events</measure>
    <time_frame>Follow-up 2: 12 months after the procedure</time_frame>
    <description>Number of participants with (serious) adverse events ≥ grade II Clavien-Dindo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural efficacy - Number of re-interventions</measure>
    <time_frame>Follow-up 2: 12 months after the procedure</time_frame>
    <description>Number of re-interventions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural efficacy - Number of post-operative recurrences</measure>
    <time_frame>Follow-up 2: 12 months after the procedure</time_frame>
    <description>Number of post-operative recurrences</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural efficacy - Number of participants with (serious) adverse events</measure>
    <time_frame>Follow-up 3: 24 months after the procedure</time_frame>
    <description>Number of participants with (serious) adverse events ≥ grade II Clavien-Dindo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural efficacy - Number of re-interventions</measure>
    <time_frame>Follow-up 3: 24 months after procedure</time_frame>
    <description>Number of re-interventions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural efficacy - Number of post-operative recurrences</measure>
    <time_frame>Follow-up 3: 24 months after the procedure</time_frame>
    <description>Number of post-operative recurrences</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural efficacy - Number of participants with (serious) adverse events</measure>
    <time_frame>Follow-up 4: 36 months after the procedure</time_frame>
    <description>Number of participants with (serious) adverse events ≥ grade II Clavien-Dindo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural efficacy - Number of re-interventions</measure>
    <time_frame>Follow-up 4: 36 months after the procedure</time_frame>
    <description>Number of re-interventions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural efficacy - Number of post-operative recurrences</measure>
    <time_frame>Follow-up 4: 36 months after the procedure</time_frame>
    <description>Number of post-operative recurrences</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-operative abdominal pain by means of the Visual Analogue Scale (VAS)</measure>
    <time_frame>At baseline</time_frame>
    <description>Assessment of pre-operative abdominal pain by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-operative vaginal pain by means of the Visual Analogue Scale (VAS)</measure>
    <time_frame>At baseline</time_frame>
    <description>Assessment of pre-operative vaginal pain by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional score - Obstructive Defecation Syndrome (ODS) score</measure>
    <time_frame>At baseline</time_frame>
    <description>The ODS score is obtained by means of a structured 8-item questionnaire on multiple bowel symptoms. The cumulative score for all answers ranges from 0 to 31, with higher scores being indicative of more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional score - Cleveland Clinical Incontinence Score (CCIS)</measure>
    <time_frame>At baseline</time_frame>
    <description>The CCIS is a 5-item questionnaire used to score the level of fecal incontinence. The cumulative score ranges from 0 to 20, with higher scores being indicative of more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - Birmingham Bowel and Urinary Symptoms Questionnaire (BBUSQ)</measure>
    <time_frame>At baseline</time_frame>
    <description>The BBUSQ is a 22-item questionnaire to record data on 4 domains: constipation, evacuation, incontinence and urinary symptoms. Higher scores are indicative of more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative abdominal pain by means of the Visual Analogue Scale (VAS)</measure>
    <time_frame>Follow-up 1: 6 - 10 weeks after the procedure</time_frame>
    <description>Assessment of post-operative abdominal pain by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative abdominal pain by means of the Visual Analogue Scale (VAS)</measure>
    <time_frame>Follow-up 2: 12 months after the procedure</time_frame>
    <description>Assessment of post-operative abdominal pain by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative abdominal pain by means of the Visual Analogue Scale (VAS)</measure>
    <time_frame>Follow-up 3: 24 months after the procedure</time_frame>
    <description>Assessment of post-operative abdominal pain by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative abdominal pain by means of the Visual Analogue Scale (VAS)</measure>
    <time_frame>Follow-up 4: 36 months after the procedure</time_frame>
    <description>Assessment of post-operative abdominal pain by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative vaginal pain by means of the Visual Analogue Scale (VAS)</measure>
    <time_frame>Follow-up 1: 6 - 10 weeks after the procedure</time_frame>
    <description>Assessment of post-operative vaginal pain by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative vaginal pain by means of the Visual Analogue Scale (VAS)</measure>
    <time_frame>Follow-up 2: 12 months after the procedure</time_frame>
    <description>Assessment of post-operative vaginal pain by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative vaginal pain by means of the Visual Analogue Scale (VAS)</measure>
    <time_frame>Follow-up 3: 24 months after the procedure</time_frame>
    <description>Assessment of post-operative vaginal pain by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative vaginal pain by means of the Visual Analogue Scale (VAS)</measure>
    <time_frame>Follow-up 4: 36 months after the procedure</time_frame>
    <description>Assessment of post-operative vaginal pain by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional score - Obstructive Defecation Syndrome (ODS) score</measure>
    <time_frame>Follow-up 1: 6 - 10 weeks after the procedure</time_frame>
    <description>The ODS score is obtained by means of a structured 8-item questionnaire on multiple bowel symptoms. The cumulative score for all answers ranges from 0 to 31, with higher scores being indicative of more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional score - Obstructive Defecation Syndrome (ODS) score</measure>
    <time_frame>Follow-up 2: 12 months after the procedure</time_frame>
    <description>The ODS score is obtained by means of a structured 8-item questionnaire on multiple bowel symptoms. The cumulative score for all answers ranges from 0 to 31, with higher scores being indicative of more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional score - Obstructive Defecation Syndrome (ODS) score</measure>
    <time_frame>Follow-up 3: 24 months after the procedure</time_frame>
    <description>The ODS score is obtained by means of a structured 8-item questionnaire on multiple bowel symptoms. The cumulative score for all answers ranges from 0 to 31, with higher scores being indicative of more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional score - Obstructive Defecation Syndrome (ODS) score</measure>
    <time_frame>Follow-up 4: 36 months after the procedure</time_frame>
    <description>The ODS score is obtained by means of a structured 8-item questionnaire on multiple bowel symptoms. The cumulative score for all answers ranges from 0 to 31, with higher scores being indicative of more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional score - Cleveland Clinical Incontinence Score (CCIS)</measure>
    <time_frame>Follow-up 1: 6 - 10 weeks after the procedure</time_frame>
    <description>The CCIS is a 5-item questionnaire used to score the level of fecal incontinence. The cumulative score ranges from 0 to 20, with higher scores being indicative of more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional score - Cleveland Clinical Incontinence Score (CCIS)</measure>
    <time_frame>Follow-up 2: 12 months after the procedure</time_frame>
    <description>The CCIS is a 5-item questionnaire used to score the level of fecal incontinence. The cumulative score ranges from 0 to 20, with higher scores being indicative of more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional score - Cleveland Clinical Incontinence Score (CCIS)</measure>
    <time_frame>Follow-up 3: 24 months after the procedure</time_frame>
    <description>The CCIS is a 5-item questionnaire used to score the level of fecal incontinence. The cumulative score ranges from 0 to 20, with higher scores being indicative of more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional score - Cleveland Clinical Incontinence Score (CCIS)</measure>
    <time_frame>Follow-up 4: 36 months after the procedure</time_frame>
    <description>The CCIS is a 5-item questionnaire used to score the level of fecal incontinence. The cumulative score ranges from 0 to 20, with higher scores being indicative of more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - Birmingham Bowel and Urinary Symptoms Questionnaire (BBUSQ)</measure>
    <time_frame>Follow-up 1: 6 - 10 weeks after the procedure</time_frame>
    <description>The BBUSQ is a 22-item questionnaire to record data on 4 domains: constipation, evacuation, incontinence and urinary symptoms. Higher scores are indicative of more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - Birmingham Bowel and Urinary Symptoms Questionnaire (BBUSQ)</measure>
    <time_frame>Follow-up 2: 12 months after the procedure</time_frame>
    <description>The BBUSQ is a 22-item questionnaire to record data on 4 domains: constipation, evacuation, incontinence and urinart symptoms. Higher scores are indicative of more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - Birmingham Bowel and Urinary Symptoms Questionnaire (BBUSQ)</measure>
    <time_frame>Follow-up 3: 24 months after the procedure</time_frame>
    <description>The BBUSQ is a 22-item questionnaire to record data on 4 domains: constipation, evacuation, incontinence and urinary symptoms. Higher scores are indicative of more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - Birmingham Bowel and Urinary Symptoms Questionnaire (BBUSQ)</measure>
    <time_frame>Follow-up 4: 36 months after the procedure</time_frame>
    <description>The BBUSQ is a 22-item questionnaire to record data on 4 domains: constipation, evacuation, incontinence and urinary symptoms. Higher scores are indicative of more severe symptoms.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Rectocele</condition>
  <condition>Enterocele</condition>
  <condition>Rectal Prolapse</condition>
  <arm_group>
    <arm_group_label>Patients eligible for laparoscopic ventral mesh rectopexy</arm_group_label>
    <description>Female patients with primary rectal prolapse, rectocele and/or enterocele eligible for laparoscopic ventral mesh rectopexy (LVMR)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ifabond (Péters surgical)</intervention_name>
    <description>Ifabond (Péters surgical) is a CE-marked synthetic surgical glue for internal and external use. The glue is non-toxic, biocompatible and biodegradable. It is commercially available and can be used for mesh fixation, as tissue adhesive, for sealing of sutured tissue and for hemostasis.</description>
    <arm_group_label>Patients eligible for laparoscopic ventral mesh rectopexy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients with primary rectal prolapse, rectocele and/or enterocele eligible for&#xD;
        laparoscopic ventral mesh rectopexy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients.&#xD;
&#xD;
          -  Patient ≥ 18 years of age at study entry.&#xD;
&#xD;
          -  Patient and investigator signed and dated the informed consent form prior to the&#xD;
             index-procedure.&#xD;
&#xD;
          -  Patient with primary rectal prolapse (grades I to V according to the Oxford scale),&#xD;
             rectocele and/or enterocele.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is unable / unwilling to provide informed consent.&#xD;
&#xD;
          -  Patient with recurrent rectal prolapse, rectocele and/or enterocele.&#xD;
&#xD;
          -  Patient is unable to comply with the study protocol or proposed follow-up visits.&#xD;
&#xD;
          -  Patient has a contra-indication for laparoscopic ventral mesh rectopexy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Dams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziekenhuis Oost-Limburg (ZOL)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie De Munter, PhD</last_name>
    <phone>+32 (0)11 28 69 48</phone>
    <email>stephanie.de.munter@archerresearch.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Dams, MD</last_name>
    <phone>+32 (0)89 32 60 20</phone>
    <email>anne.dams@zol.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg (ZOL)</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Dams, MD</last_name>
      <phone>+32 (0)89 32 60 20</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Prolapse</mesh_term>
    <mesh_term>Rectocele</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Hernia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

